123 related articles for article (PubMed ID: 12665323)
1. Has the time come for routine use of amifostine in clinical radiotherapy practice?
Lindegaard JC
Acta Oncol; 2003; 42(1):2-3. PubMed ID: 12665323
[No Abstract] [Full Text] [Related]
2. Improved tolerability of amifostine with rapid infusion and optimal patient preparation.
Boccia R
Semin Oncol; 2002 Dec; 29(6 Suppl 19):9-13. PubMed ID: 12577237
[TBL] [Abstract][Full Text] [Related]
3. Future development of amifostine as a radioprotectant.
Werner-Wasik M
Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272
[TBL] [Abstract][Full Text] [Related]
4. Protection of normal tissues from the cytotoxic effects of radiation therapy: focus on amifostine.
Mehta MP
Semin Radiat Oncol; 1998 Oct; 8(4 Suppl 1):14-6. PubMed ID: 9794996
[TBL] [Abstract][Full Text] [Related]
5. A new administration schedule for amifostine as a radioprotector in cancer therapy.
Wagner W; Radmard A; Schönekaes KG
Anticancer Res; 1999; 19(3B):2281-3. PubMed ID: 10472344
[TBL] [Abstract][Full Text] [Related]
6. Daily subcutaneous amifostine administration during irradiation of pediatric head and neck cancers.
Anacak Y; Kamer S; Haydaroglu A
Pediatr Blood Cancer; 2007 May; 48(5):579-81. PubMed ID: 16395679
[TBL] [Abstract][Full Text] [Related]
7. Amifostine and hematologic effects.
Sriswasdi C; Jootar S; Giles FJ
J Med Assoc Thai; 2000 Apr; 83(4):374-82. PubMed ID: 10808697
[TBL] [Abstract][Full Text] [Related]
8. Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: a retrospective analysis.
Kouloulias VE; Kouvaris JR; Kokakis JD; Kostakopoulos A; Mallas E; Metafa A; Vlahos LJ
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1148-56. PubMed ID: 15234050
[TBL] [Abstract][Full Text] [Related]
9. Individualization of the subcutaneous amifostine dose during hypofractionated / accelerated radiotherapy.
Koukourakis MI; Abatzoglou I; Sivridis L; Tsarkatsi M; Delidou H
Anticancer Res; 2006; 26(3B):2437-43. PubMed ID: 16821629
[TBL] [Abstract][Full Text] [Related]
10. [New data on cytoprotection in radiotherapy].
Sauer R; Strnad V
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():1. PubMed ID: 10584131
[No Abstract] [Full Text] [Related]
11. Has the outlook improved for amifostine as a clinical radioprotector?
Lindegaard JC; Grau C
Radiother Oncol; 2000 Nov; 57(2):113-8. PubMed ID: 11054513
[TBL] [Abstract][Full Text] [Related]
12. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.
Schuchter LM; Hensley ML; Meropol NJ; Winer EP;
J Clin Oncol; 2002 Jun; 20(12):2895-903. PubMed ID: 12065567
[No Abstract] [Full Text] [Related]
13. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
Altmann S; Hoffmanns H
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
[TBL] [Abstract][Full Text] [Related]
14. Managing toxicities in pelvic malignancies.
Friedland J
J Support Oncol; 2004; 2(6 Suppl 3):19-23. PubMed ID: 15605921
[TBL] [Abstract][Full Text] [Related]
15. Clinical applications of radioprotectors.
Werner-Wasik M
Expert Rev Anticancer Ther; 2001 Aug; 1(2):309-16. PubMed ID: 12113036
[TBL] [Abstract][Full Text] [Related]
16. [Combined use of amifostine and misonidazole in experimental radiotherapy].
Tsukiyama I
Nihon Igaku Hoshasen Gakkai Zasshi; 1983 Apr; 43(4):613-21. PubMed ID: 6310492
[No Abstract] [Full Text] [Related]
17. Effects of amifostine on radiation-induced cardiac damage.
Kruse JJ; Strootman EG; Wondergem J
Acta Oncol; 2003; 42(1):4-9. PubMed ID: 12665324
[TBL] [Abstract][Full Text] [Related]
18. [Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
Vacha P; Marx M; Engel A; Richter E; Feyerabend T
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():18-22. PubMed ID: 10584135
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study.
Koukourakis MI; Kyrias G; Kakolyris S; Kouroussis C; Frangiadaki C; Giatromanolaki A; Retalis G; Georgoulias V
J Clin Oncol; 2000 Jun; 18(11):2226-33. PubMed ID: 10829042
[TBL] [Abstract][Full Text] [Related]
20. Cytoprotective effect of amifostine in radiation-induced acute mucositis - a retrospective analysis.
Kouvaris J; Kouloulias V; Kokakis J; Matsopoulos G; Balafouta M; Miliadou A; Vlahos L
Onkologie; 2002 Aug; 25(4):364-9. PubMed ID: 12232489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]